Novartis has entered into a development and licensing agreement with Biological E of India for two vaccines to protect against typhoid and paratyphoid fevers.
News
Novartis psoriasis drug beats Amgen’s Enbrel in Ph III
Novartis’ secukinumab has outperformed Amgen’s multi-billion-dollar drug Enbrel in a late-stage clinical trial in patients with psoriasis.
Oil-rich Azerbaijan “very attractive” for pharma
The oil-rich and rapidly-growing nation of Azerbaijan is presenting itself as a very attractive ground for global healthcare investors, and the nation’s pharmaceutical market is particularly promising, according to new research.
China starts probe into pharma pricing
Days after beginning an investigation into price-fixing of infant milk by foreign companies, China has turned its attention to the pharmaceutical industry, both domestic and international.
Fresh EU approval for Novartis’ Lucentis
The European Commission has granted Novartis a fourth approval for its eye drug Lucentis, this time to treat patients with visual impairment due to choroidal neovascularisation secondary to pathologic myopia.
Orexo gets FDA OK for opioid dependence drug
Regulators in the USA have given the green light to Orexo of Sweden’s Zubsolv as a treatment for opioid addiction.
GSK tests ofatumumab in rare skin disorder
GlaxoSmithKline is to start a new Phase III study of ofatumumab as a treatment for pemphigus vulgaris, a rare autoimmune disorder of the skin, according to partner Genmab.
Imperial signs up for £30m loan to invest in UK biotech
UK investment group Imperial innovations has bagged a £30-million, 12-year loan from the European Investment Bank to plug into the country’s biotech and therapeutics sectors.
New problems for NHS 111 as NHS Direct drops contracts
Embattled urgent care telephone triage line NHS 111 has been dealt a further blow after NHS Direct confirmed it has pulled out of two contracts to provide the service, with the future of others in doubt.
No progress in bowel cancer emergency admissions, audit finds
The number of patients with bowel cancer admitted to hospital as an emergency case has stayed level over the last four years, remaining at a “stubborn” 21%-22%, or one in five patients.
Paraxel signs up Rutgers New Jersey Medical School as Key Alliance Site
US-based biopharmaceutical services provider Parexel International has designated Rutgers New Jersey Medical School (NJMS) in Newark as a Key Alliance Site for hosting clinical trials from Parexel’s client base.
Single shot of Biogen’s haemophilia drug controls 87% of bleeds
Biogen Idec and Swedish Orphan Biovitrum (Sobi) have unveiled late-stage clinical data that seem to support the clinical and safety profile of their long-lasting recombinant factor VIII candidate Eloctate, which is currently under review for haemophilia A.
US priority review for Roche’s ‘breakthrough’ leukaemia drug
US regulators will conduct an accelerated review of Roche group Genentech’s ‘breakthrough’ leukaemia drug obinutuzumab.
Canada’s Rx drug coverage system “unsustainable”
Canada’s current “patchwork” system of prescription drug coverage is pushing up costs, creates massive confusion and results in significant financial hardship for some Canadians, insurance leaders have warned.
CFR of Chile in talks to buy South Africa’s Adcock Ingram
Chilean branded generics major CFR Pharmaceuticals (Corporacion Farmaceutica Recalcine) is making a cash and shares offer to buy South African group Adcock Ingram in a deal valued at 12.90 billion rand, around $1.30 billion.
